Skip to content 
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. more
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | 241.25M | 239.72M | 275.65M | 1.11B | [{"date":"2022-12-31","value":21.69,"profit":true},{"date":"2023-12-31","value":21.55,"profit":true},{"date":"2024-12-31","value":24.78,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Cost of Revenue | - | - | 34.86M | 29.74M | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":85.29,"profit":true}] | |
| Gross Profit | 241.25M | 239.72M | 240.79M | 1.08B | [{"date":"2022-12-31","value":22.29,"profit":true},{"date":"2023-12-31","value":22.15,"profit":true},{"date":"2024-12-31","value":22.24,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Gross Margin | 100.00% | 100.00% | 87.35% | 97.33% | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":87.35,"profit":true},{"date":"2025-12-31","value":97.33,"profit":true}] | |
| Operating Expenses | 372.31M | 327.99M | 463.99M | 581.12M | [{"date":"2022-12-31","value":64.07,"profit":true},{"date":"2023-12-31","value":56.44,"profit":true},{"date":"2024-12-31","value":79.84,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Operating Income | (131.06M) | (88.26M) | (188.34M) | 501.39M | [{"date":"2022-12-31","value":-26.14,"profit":false},{"date":"2023-12-31","value":-17.6,"profit":false},{"date":"2024-12-31","value":-37.56,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] | |
| Total Non-Operating Income/Expense | 60.21M | 93.89M | 185.25M | (155.33M) | [{"date":"2022-12-31","value":32.5,"profit":true},{"date":"2023-12-31","value":50.68,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":-83.85,"profit":false}] | |
| Pre-Tax Income | (70.85M) | 5.63M | (3.08M) | 300.87M | [{"date":"2022-12-31","value":-23.55,"profit":false},{"date":"2023-12-31","value":1.87,"profit":true},{"date":"2024-12-31","value":-1.03,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] | |
| Income Taxes | - | - | - | (18.62M) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":-1862100000,"profit":false}] | |
| Income After Taxes | - | - | - | 319.49M | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| Income From Continuous Operations | (71.42M) | (3.99M) | (1.28M) | 319.49M | [{"date":"2022-12-31","value":-22.35,"profit":false},{"date":"2023-12-31","value":-1.25,"profit":false},{"date":"2024-12-31","value":-0.4,"profit":false},{"date":"2025-12-31","value":100,"profit":true}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Net Income | (217.99M) | 211.70M | 74.08M | 320.88M | [{"date":"2022-12-31","value":-67.93,"profit":false},{"date":"2023-12-31","value":65.97,"profit":true},{"date":"2024-12-31","value":23.09,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
| EPS (Diluted) | (3.41) | - | 2.09 | 8.71 | [{"date":"2022-12-31","value":-39.19,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":23.99,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| LKFT | |
|---|---|
| Cash Ratio | 29.70 |
| Current Ratio | 30.48 |
| Quick Ratio | 30.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LKFT | |
|---|---|
| ROA (LTM) | 10.66% |
| ROE (LTM) | 16.26% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LKFT | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.04 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.96 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LKFT | |
|---|---|
| Trailing PE | 3.20 |
| Forward PE | 344.83 |
| P/S (TTM) | 1.74 |
| P/B | 0.48 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Lakefront Biotherapeutics NV (LKFT) share price today is $27.49
Yes, Indians can buy shares of Lakefront Biotherapeutics NV (LKFT) on Vested. To buy
Yes, you can purchase fractional shares of Lakefront Biotherapeutics NV (LKFT) via the Vested app. You can start investing in Lakefront Biotherapeutics NV (LKFT) with a minimum investment of $1.
You can invest in shares of Lakefront Biotherapeutics NV (LKFT) via Vested in three simple steps:
The 52-week high price of Lakefront Biotherapeutics NV (LKFT) is $29.77. The 52-week low price of Lakefront Biotherapeutics NV (LKFT) is $26.42.
The price-to-earnings (P/E) ratio of Lakefront Biotherapeutics NV (LKFT) is 3.1977
The price-to-book (P/B) ratio of Lakefront Biotherapeutics NV (LKFT) is 0.48
The dividend yield of Lakefront Biotherapeutics NV (LKFT) is 0.00%
The market capitalization of Lakefront Biotherapeutics NV (LKFT) is $1.83B
The stock symbol (or ticker) of Lakefront Biotherapeutics NV is LKFT
Consider the share price of Lakefront Biotherapeutics NV as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Lakefront Biotherapeutics NV has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Lakefront Biotherapeutics NV shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Lakefront Biotherapeutics NV stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Lakefront Biotherapeutics NV and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Lakefront Biotherapeutics NV stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
